These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 608549)

  • 1. Prospects for immunotherapy.
    Woodruff MF
    Dev Biol Stand; 1977 Apr 13-15; 38():573-80. PubMed ID: 608549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
    Zöller M; Matzku S
    Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunotherapy of solid tumors. Current status and prospects].
    Valente MG; Tagliaferri F; Stipa F; Arklins K; Cesareo S; Sirovich I
    Recenti Prog Med; 1996; 87(7-8):358-61. PubMed ID: 8975338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal residual disease as the target for immunotherapy and gene therapy of cancer (review).
    Bubeník J; Símová J
    Oncol Rep; 2005 Nov; 14(5):1377-80. PubMed ID: 16211312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunotherapy.
    Baxevanis CN; Perez SA; Papamichail M
    Crit Rev Clin Lab Sci; 2009; 46(4):167-89. PubMed ID: 19650714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cell based immunotherapy--a promising therapeutic approach for endocrine malignancies.
    Sbiera S; Wortmann S; Fassnacht M
    Horm Metab Res; 2008 Feb; 40(2):89-98. PubMed ID: 18283626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy of renal cell carcinoma.
    deKernion JB
    Prog Clin Biol Res; 1984; 153():409-21. PubMed ID: 6206509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cells for specific cancer immunotherapy.
    Meidenbauer N; Andreesen R; Mackensen A
    Biol Chem; 2001 Apr; 382(4):507-20. PubMed ID: 11405216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large-scale randomised trials--a misguided approach to clinical research.
    Penston J
    Med Hypotheses; 2005; 64(3):651-7. PubMed ID: 15617882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Problems and prospects of new immunotherapeutic approaches.
    Fridman WH; Mathiot C; Michon J; Teillaud JL; Dorval T; Zucker JM; Pouillart P
    Cancer Detect Prev; 1990; 14(6):657-60. PubMed ID: 2257565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgeons: A Future Role in Clinical Trials?
    Rusch VW
    Oncologist; 1997; 2(3):V-VI. PubMed ID: 10388050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy.
    Schultze JL; Grabbe S; von Bergwelt-Baildon MS
    Trends Immunol; 2004 Dec; 25(12):659-64. PubMed ID: 15530836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune monitoring of cancer patients undergoing experimental immunotherapy.
    Shankar G; Salgaller ML
    Curr Opin Mol Ther; 2000 Feb; 2(1):66-73. PubMed ID: 11249653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospects for the therapeutic use of human monoclonal antibodies.
    Larrick JW; Bourla JM
    J Biol Response Mod; 1986 Oct; 5(5):379-93. PubMed ID: 3534144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Dendrite cell-based cancer vaccines--clinical application].
    Svane IM; Berntsen A; Trepiakas R; Pedersen AE
    Ugeskr Laeger; 2006 Apr; 168(14):1415-20. PubMed ID: 16584668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active specific T-cell-based immunotherapy for cancer: nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects.
    Fernandez N; Duffour MT; Perricaudet M; Lotze MT; Tursz T; Zitvogel L
    Cytokines Cell Mol Ther; 1998 Mar; 4(1):53-65. PubMed ID: 9557217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.